What is the drug of choice for Thalassemia?

AIIMS Raipur NO - 2019 (Shift-1)

Pharmacology

Medium

Appeared in: AIIMS Raipur NO - 2019 (Shift-1)

Explanation

Patients with severe thalassemia require frequent blood transfusions to manage anemia, which leads to a complication known as iron overload or secondary hemochromatosis.
Deferoxamine is an iron-chelating agent, meaning it binds with excess iron in the bloodstream and tissues.
This binding forms a complex that is then excreted from the body, primarily through the urine.
By removing excess iron, deferoxamine prevents toxic accumulation in vital organs like the heart, liver, and endocrine glands, which is the primary goal of this therapy.

Option A: Vincristine is a chemotherapy drug (vinca alkaloid) used to treat various cancers, such as leukemia and lymphoma. It has no role in treating thalassemia or its complications.
Option B: Vinblastine is also a vinca alkaloid used in cancer treatment, particularly for Hodgkin's lymphoma and testicular cancer. It does not address the underlying issues of thalassemia.
Option C: Dilantin (phenytoin) is an anticonvulsant medication used to control and prevent seizures. It has no therapeutic effect on blood disorders like thalassemia or on iron levels.

Clinical Relevance

Nursing practice connection: Knowing Pharmacological management of complications associated with Thalassemia helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
The primary cause of mortality in transfusion-dependent thalassemia is cardiac disease from iron overload. Effective and consistent chelation therapy is a cornerstone of nursing management to improve patient survival and quality of life.
Nurses are responsible for administering deferoxamine, typically via a subcutaneous pump, and must educate the patient on operating the pump, rotating injection sites, and recognizing signs of local irritation or infection.
What if? If a patient on deferoxamine reports sudden hearing loss or changes in vision, the nurse must immediately withhold the dose and notify the healthcare provider. These are signs of serious neurotoxicity, which may be irreversible if not addressed promptly.

How to Approach the Question

First, identify the core disease mentioned: Thalassemia. Recall that severe forms of this genetic blood disorder require lifelong blood transfusions.
Next, consider the primary long-term complication of chronic blood transfusions. This is iron overload (hemosiderosis), as the body has no natural way to excrete the excess iron from transfused red blood cells.
Analyze the question's prompt, which asks for the 'drug of choice'. This implies a treatment for either the disease itself or its main complication.
Evaluate the options based on their drug class and mechanism of action. Vincristine and Vinblastine are chemotherapy agents. Dilantin is an anti-seizure medication. Deferoxamine is an iron chelator.
Connect the drug's function to the problem. An iron chelator is specifically designed to remove excess iron. Therefore, it directly addresses the major complication of thalassemia treatment.
Conclude that Deferoxamine is the logical drug of choice for managing patients with thalassemia who have transfusional iron overload.

Concept Tested & Keywords

Concept Tested: Pharmacological management of complications associated with Thalassemia.
Stem keywords: drug of choice, Thalassemia
Lead-in keywords: What is